The Food & Drug Administration (FDA) authorized the first-ever vaccine against Respiratory syncytial Virus (RSV) on May 3. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older. Nursing homes should follow up with their long-term care pharmacies for more information and planning.